Yonsei University: Liver Diseases trials

The registry lists 12 Liver Diseases studies with Yonsei University as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 1Phase 3 1Phase 4 5No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Antidiabetic Drugs for Steatotic Liver DiseaseCompletedNCT03646292Phase 4
• Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver DiseaseCompletedNCT03434613Phase 4
• Development and Clinical Application of Invalid Foods Using MealwormsStatus unknownNCT03201926Not applicable
• Weight Loss Effect on Circulating Liver EnzymesCompletedNCT02992639Not applicable
• Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver ResectionTerminatedNCT02710266Phase 3
• Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative StressCompletedNCT02650830
• A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver TransplantationCompletedNCT02504138Phase 4
• Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLDStatus unknownNCT02285218
• A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLDCompletedNCT02285205Phase 4
• Evaluation of Liver Fibrosis Staging With Acoustic Radiation Force Impulse ElastographyCompletedNCT01283230
• Effect of Candesartan in Alcoholic Liver FibrosisCompletedNCT00990639Phase 1/2
• Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease PatientsStatus unknownNCT00823550Phase 4